What the FDA labels say about taking them together
Glucagon and insulin glargine
Insulin glargine's FDA label of June 16, 2026 names glucagon in its drug interactions section; glucagon's label does not name insulin glargine itself but warns about its class (insulin analogs). The insulin glargine label: “Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives …”
Check it at the source: the glucagon FDA label on DailyMed (effective August 11, 2026, Amphastar Pharmaceuticals, Inc.); the insulin glargine FDA label on DailyMed (effective June 16, 2026, Eli Lilly and Company).
What does the glucagon label say about insulin glargine?
Glucagon's label does not name insulin glargine itself; it warns about its class (insulin analogs):
Glucagon label, drug interactionsMonitor blood glucose when Glucagon for Injection is used as a diagnostic aid in patients receiving insulin.
Glucagon label, warnings and precautionsIn patients with insulinoma, glucagon administration may produce an initial increase in blood glucose; however, Glucagon for Injection may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia.
Source: FDA drug label (Glucagon), Amphastar Pharmaceuticals, Inc., effective August 11, 2026 (SPL set 8cc40354-b5ac-45b6-a211-93b44444f2a3), via openFDA; the full label on DailyMed
What does the insulin glargine label say about glucagon?
Insulin glargine label, drug interactionsDrugs That May Decrease the Blood Glucose Lowering Effect of BASAGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones Intervention: Dose increases and increased frequency of glucose monitoring may be required when BASAGLAR is co-administered with these drugs.
Source: FDA drug label (Insulin Glargine, BLA761201), Biocon Biologics Inc., effective January 23, 2026 (SPL set 3ac85ebb-5594-59c8-77fd-df254329d151), via openFDA
Source: FDA drug label (Lantus Solostar, BLA021081), sanofi-aventis U.S. LLC, effective June 2, 2025 (SPL set d5e07a0c-7e14-4756-9152-9fea485d654a), via openFDA
Source: FDA drug label (Toujeo, BLA206538), Sanofi-Aventis U.S. LLC, effective May 30, 2025 (SPL set c9561d96-124d-48ca-982f-0aa1575bff36), via openFDA
Source: FDA drug label (BASAGLAR KwikPen), Eli Lilly and Company, effective June 16, 2026 (SPL set 0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Glucagon | Insulin glargine | |
|---|---|---|
| Labeled for | n/a | Type 2 diabetes, Type 1 diabetes |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $154.20 per kit 1 mg emergency kit | $2.90 per mL 100 pen |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once